Results of multivariate Cox regression analysis on factors associated with CNS relapse in the COO and BCL2/MYC dual-expression status–available population (n = 688)
| Factor . | HR* . | 95% CI . | P . |
|---|---|---|---|
| CNS-IPI intermediate (vs low) | 0.75 | 0.23-2.45 | .6378 |
| CNS-IPI high (vs low) | 2.76 | 0.81-9.42 | .1042 |
| ABC COO (vs GCB) | 4.78 | 1.49-15.29 | .0084 |
| Unclassified COO (vs GCB) | 4.24 | 1.32-13.61 | .0151 |
| BCL2/MYC dual expresser (vs nondual expresser) | 0.83 | 0.34-2.06 | .6931 |
| Factor . | HR* . | 95% CI . | P . |
|---|---|---|---|
| CNS-IPI intermediate (vs low) | 0.75 | 0.23-2.45 | .6378 |
| CNS-IPI high (vs low) | 2.76 | 0.81-9.42 | .1042 |
| ABC COO (vs GCB) | 4.78 | 1.49-15.29 | .0084 |
| Unclassified COO (vs GCB) | 4.24 | 1.32-13.61 | .0151 |
| BCL2/MYC dual expresser (vs nondual expresser) | 0.83 | 0.34-2.06 | .6931 |
CNS relapses, n = 22. Factors that were significantly associated with greater CNS relapse risk are highlighted in bold.
Adjusted for study randomization stratification factors (number of planned chemotherapy cycles, geographic region).